• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    There is provided a novel and efficient stereoselective total synthesis of epipodophyllotoxin and related epipodophyllotoxin compounds of the general formula <IMAGE> wherein R1 and R2 each are independently hydrogen or (lower)alkoxy, or R1 and R2, taken together, is methylenedioxy; R4 and R6 each are independently hydrogen or (lower)alkoxy; and R5 is hydrogen or a phenol-protecting group; or an acid addition salt thereof. The present invention also provides novel intermediates and processes for the preparation of said intermediates, which are then converted into known antineoplastic agents.
    公开号:SU1547707A3
    申请号:SU874028952
    申请日:1987-02-10
    公开日:1990-02-28
    发明作者:М.Виас Долэтрай；М.Сконезни Пол
    申请人:Бристоль-Мейерз Компани (Фирма)；
    IPC主号:
    专利说明:

    These conditions increase the yield of the target product from 43-57 to 90% while reducing the duration of the process from 4-16 days to 2.5 hours.
    The invention relates to an improved process for the preparation of trans-ethyl-1, 2, 3,4-tetrahydro-6,7-methylenedioxy-5-oKco-l- (3,4,5-trimethoxyphenyl) naphthalene-2-carboxylate , An intermediate in the synthesis of the biologically active compound - epipodophyllotoxin, which has cytotoxic activity.
    CM
    The purpose of the invention is to increase the yield of the target product and intensify the process.
    The melting point was determined using a Thomas-Hoover apparatus by measuring the melting point of a substance in a capillary using a Bruker WM 360 spectrometer and CDC13. The chemical displacements are expressed in f units, the constant JQ bonds are expressed in Hertz. Resonance splitting of the spectrum was designated as follows: s.-singlet, d., Doublet, t., Tritslet, K., quartet, m using coated silica gel plates (60F-254) and using ultraviolet rays and / or vapors. iodine as a means of visualization. Flash chromatography was performed using Woelm silica gel (32-63 µm) and the indicated solvents. All solvent evaporations were carried out under reduced pressure. Used in this description, the term |: Skellisolf B |: is a fraction of petroleum solvent and with a bp. in the range of 60-68 ° C, consisting
    cartoon, etc. - wide peak, and d. 5 of n-hexane, and the term ether
    doublet doublet. Infrared spectra means simple diethyl zfir, if there was no other definition using spectrophotometers, the Beckmann model 4240 was presented as Example 1. Ethyl 2- (2,4-methines in inverse centimeters. Thin-lendioxybenzoyl) -3- (3, 4,5-trimetonoux chromatography (TLC) was performed with 20xyphenyl) cycloprop ancarboxylate II
    In a three-neck round-bottom one-liter flask equipped with a magnetic stirrer, dropping funnel, introductory
    a pipe for nitrogen and a membrane; sodium hydride (8.2 g 0.17 mol, 5-0% dispersion) is added. This dispersion is washed with petroleum ether (ml) and dried in nitrogen. Trimethylsulfoxonium iodide (37.7 g, 0.17 mol) was injected, and then dehydrated dimethyl sulfoxide (45 ml) was added dropwise via a syringe over 30 minutes. The suspension is stirred at room temperature for 1.5 hours and a solution of carbethoxymethyldimethylsulfonium bromide (41.2 g, 0.18 mol) is introduced for 10 minutes under continuous stirring conditions. The milky white suspension is then further stirred at room temperature for 1.5 hours. Suspension of 3,4,5-trimethoxy (3U, 4-methylenedioxychalcone III) (55.9 g, 0 , 16 mol) in dimethyl sulfoxide (185 ml), and then this reaction using coated silica gel plates (60F-254) and using ultraviolet rays and / or iodine vapor as visualization tools. Flash chromatography was performed using Woelm silica gel (32-63 µm) and the indicated solvents. All solvent evaporations were carried out under reduced pressure. Used in this description, the term |: Skellysolph B |: is a fraction of petroleum solvent and with a bp. in the range of 60-68 C, consisting
    СООС2Н5
    five

    The mixture was stirred at room temperature for 17 hours. The reaction mixture was poured into cold 0.1 N. hydrochloric acid (700 ml) and the resulting resinous material are separated from the aqueous solution. The TS solution is extracted with ether (diethyl) (ml). The combined extract together with an additional amount of ether (500 ml) is used to dissolve the indicated resinous precipitate. The ethereal solution is then washed successively with an aqueous solution of NaHC03 (500 ml, 5%) and water, dried (over and MgSO4) and evaporated, to give the d isomer of the target compound (68.0 g) as a light yellow glassy substance.
    The 1H NQR spectrum of this product was identical to the spectrum of al. the isomer described previously.
    In the next experiment, trimethylsulfoxonium iodide, which was used in the procedure described above, was not introduced into the reaction mixture, ultimately it was also obtained with the I-isomer of the target compound in high yield. Carbotoxymethyl dimethylsulfonium bromide (2.98 g 1.2 mmol) is added to a solution of sodium hydride (0.67 g 1.4 mmol) in the form of a 50% dispersion, in 10 ml of anhydrous dimethyl sulfoxide. additionally 19 ml of dimethyl sulfoxide. After about 75 minutes, a solution of chalcone III (3.42 g, 1.0 mMol) in 21 ml of tetrahydrofuran and 4 ml of dimethyl sulfoxide was slowly introduced over 35 minutes.
    The reaction mixture was worked up in the same manner as in the procedure described above, and the o / -isomer of the target compound was obtained in a yield of 96%.
    Example 2. Trans-ethyl-1,2,3,4-tetrahydro-6,7-methylenedioxy-4-oxy-1- (3,4,5-trimethoxyphenyl) naphthalene-2-carboxalate T
    С02С2Н5
    С02С2Н5
    sn.o
    BF3-Et O (0.24 ml, 19 mmol) is added to a solution of cyclopropyl ketone TI (0.8 g, 1.9 mM) in methylene chloride (40 ml), followed by the introduction of acetic anhydride (0.36 ml, 3.8 mMol) The solution is stirred at room temperature for 2.5 hours and then diluted with 0.2N. sodium hydroxide solution (50 ml) and methylene chloride (50 ml). The organic layer is separated, washed with water, dried over MgSO4 and evaporated to an oily solid (0.72 g). After recrystallization from absolute ethanol by treatment with charcoal, the target compound is obtained as a white crystalline solid (0.46 g), 157-159 ° C. The 1H NMR spectral data were identical to those obtained for compound I previously.
    Example 3. Trans-ethyl-1,2,3,4-tetrahydro-6,7-methylenedioxy-4-oxo-g -1t (3,3,5-trimethoxyphenium) naphthalene-2-carboxylate.
    20
    25
    thirty
    35
    40
    45
    50
    55
    The procedure was carried out as in Example 2, using 50 mg (0.12) of cyclopropyl ketone II with the difference that nitromethane was used instead of methylene chloride, resulting in 45 mg of the desired product. Analysis by thin layer chromatography (silica gel) ether: Skellysolph B (3: 2) shows the value of R, - 0.26. The 1H NMR spectrum data was identical to the data for the product obtained in Example 2.
    Example 4. Trans-ethyl-1,2,3,4-tetrahydro-6,7-methylenedioxy-4-oxo--1- (3,4,5-trimethoxyphenyl) naphthalene-2-carboxylate.
    a) The procedure as in Example 2 was carried out in methylene chloride with 50 mg (0.32 mmol) of cyclopropyl ketone II with the difference that SuCl 4 was used instead of BFj-ECO, resulting in the desired compound in 90% yield.
    c) Carry out the procedure as described above in a) with the difference that nitromethane is used instead of methylene chloride, the result is the target compound with a yield of 90%.
    c) Carry out the procedure as described above in a) with the difference that benzene is used instead of methylene chloride to obtain the desired compound.
    Analysis by thin layer chromatography (silica gel) ether: Skellysolph B (3: 2) of each of the three above products showed a Pr value of 0.26, IH NMR data was identical to the data for the product obtained according to example 2.
    ten
    Example 5. Trans-ethyl-1,2,3,4-tetrahydro-6,7-methylenedioxy-4-oxo--1 - (3,4,5-trimethoxyphenyl) naphthalene-2-carboxylate.
    The procedure is carried out as described in Example 3, with 428 mg (1.0 mMol) of cyclopropyl ketone II and 204 mg (2.0 mmol) of acetic anhydride in 5 ml of nitrometane with the difference that instead of I equivalent to BFj -Et 0 use 0.5 equivalents of BF3-Et20 (71 mg, 0.5 mmol), the result is the target compound. The data of 1H NMR spectrum of this product j were identical to those of the product obtained according to example 3.
    Example 6. Trans-ethyl-1,2,3,4-tetrahydro-6,7-methylenedioxy-4-ox-1- (3,4,5-trimethoxyphenyl) naphtha-20 lin-2-carboxylate I.
    In a solution of cyclopropyl ketone II (428 mg, 1.0 mMol) in 5 ml of nitromethane, a catalytic active amount of acetic anhydride 25 (10.2 mg, 0.1 mMol) is introduced, and then BMA of Et40 (142 mg, J, 0 mM). The reaction mixture is stirred at room temperature, then subjected to liquid chromatography under high pressure. After about 100 hours, the reaction mixture is treated with 10 ml of 0.2N. NaOH and diluted with 5 ml. methylene chloride. The organic phase is separated, dried and evaporated under reduced pressure, to give the desired compound. The data of the IFMR spectrum of this product were identical to the data of the spectrum of the product obtained according to Example 2, except for the fact that some impurities were found in it.
    The proposed method allows to increase the yield of the target product up to 90% (against 43-57%) and reduce the time of the pro-45 process from 4-16 days to 2.5 hours.
    权利要求:
    Claims (1)
    [1]
    Invention Formula
    The method of obtaining trans-ethyl-1,2, 3,4-tetrahydro-6,7-methylenedioxy-4-oxo-1- (3,4,5-trimethoxyphenyl) naphthalene-2-carboxylate of formula
    СООС2Н5
    sneak
    by allowing catalytic cyclization with a Lewis acid such as or SuCl4 at room temperature in an inert organic solvent of a cyclopropyl compound of the formula
    СООС2Н5
    Ш30
    axle axis
    characterized in that, in order to increase the yield of the target product and intensify the process, cyclization is carried out in the presence of 0.5-1 equivalent of Lewis acid and two equivalents of acetic anhydride, and nitromethane, methylene chloride or benzene are used as inert organic solvent.
    类似技术:
    公开号 | 公开日 | 专利标题
    Sidebottom et al.1992|The squalestatins, novel inhibitors of squalene synthase produced by a species of Phoma II. Structure elucidation
    SU1547707A3|1990-02-28|Method of producing trans-ethyl-1,2,3,4-tetrahydro-6,7-methylenedioxy-4-oxo-1|naphthalene-2-carboxylate
    HU198439B|1989-10-30|Process for producing alpha-aryl-alkan-acids
    Krüger et al.1998|Convergent synthesis of the amphotericin polyol subunit employing asymmetric dienolate addition reactions
    Kaiser et al.1984|Catalytic hydrogenation of pyrroles at atmospheric pressure
    CN111511357A|2020-08-07|Process for the preparation of talofu
    EP0496238A1|1992-07-29|Substituted benzoxazepines and benzothiazepines, process for their preparation and their use as medicaments
    US5196607A|1993-03-23|Process for preparing ketone enantiomer
    Harmata et al.1995|Intramolecular [4+ 3] cycloadditions. Studies of relative asymmetric induction
    EP0214426B1|1991-01-23|Intermediates in the synthesis of carboxylic acids
    Jeffs et al.1982|Sceletium alkaloids. Part 12. Synthesis of |-mesembranol and |-O-methyljoubertiamine. Aza-ring expansion of cis-bicyclo [4.2. 0] octanones
    EP0095835B1|1986-11-05|Preparing 4,7-dialkoxybenzofurans, and intermediates used therein
    GB2036744A|1980-07-02|Eburnane derivatives
    Nakagawa et al.1988|A stereospecific total synthesis of |-gephyrotoxin 223AB
    EP0300249B1|1993-02-03|7-[1H-pyrrol-3-yl]-substituted 3,5-dihydroxy-heptane acids, their corresponding delta-lactones and salts, processes for their manufacture, their use as medicines, pharmaceutical preparations and intermediates
    Piers et al.1969|Total synthesis, stereochemistry, and lithium–ammonia reduction of |-4-demethylaristolone and |-5-epi-4-demethylaristolone
    Sato et al.2020|Access of cis-4-monofluoromethyl-1, 3-oxazolidines via a formal [3+ 2] cycloaddition triggered by BF3• OEt2
    US4855437A|1989-08-08|Prostanoids and synthesis thereof
    Satoh et al.1993|Favorskii Rearrangement and Carbon–Carbon Bond-Cleavage of α-Chloro-α-sulfonyl Ketones: A Synthesis of Carboxylic Acids and Their Derivatives from Aldehydes and Ketones
    CN108774170B|2021-05-14|Octahydroacridine skeleton with three continuous chiral centers and preparation method thereof
    US5013862A|1991-05-07|Prostanoids and synthesis thereof
    Tsuboi et al.1987|A facile synthesis of γ-alkylidene-α, β-unsaturated γ-lactones
    Mitra et al.1989|A Facile Synthesis of Ethyl 3-Aryl-2, 2-dimethyl-cyclopropanecarboxylates, Intermediates for Pyrethroid Acaricides
    KR100275039B1|2000-12-15|A method for producing cyclopentadec-2-enone for synthesis of mouscone
    EP0138849B1|1988-04-27|Process for the preparation of lineatin
    同族专利:
    公开号 | 公开日
    ES557772A0|1988-11-16|
    YU112487A|1988-02-29|
    CY1599A|1992-04-03|
    KR860008198A|1986-11-12|
    AU587021B2|1989-08-03|
    HK53391A|1991-07-19|
    HU199846B|1990-03-28|
    DK117193D0|1993-10-18|
    HU204044B|1991-11-28|
    FI861508A|1986-10-13|
    FR2587335A1|1987-03-20|
    FR2587335B1|1990-09-14|
    SE468768B|1993-03-15|
    NL8600938A|1986-11-03|
    IE860955L|1986-10-12|
    HUT47088A|1989-01-30|
    CH669190A5|1989-02-28|
    MY101618A|1991-12-17|
    ES8900046A1|1988-11-16|
    AU3628689A|1989-10-05|
    PT82383A|1986-05-01|
    SE8601646D0|1986-04-11|
    AU617184B2|1991-11-21|
    GR860982B|1986-09-01|
    DE3612278A1|1986-10-16|
    SE8601646L|1986-11-28|
    AU5599386A|1986-10-16|
    AU3628789A|1989-10-05|
    CN86102404A|1986-12-03|
    DK117193A|1993-10-18|
    HUT47071A|1989-01-30|
    CH672635A5|1989-12-15|
    KR900005624B1|1990-08-01|
    ES553868A0|1988-03-16|
    RU1819265C|1993-05-30|
    AU617185B2|1991-11-21|
    SE9202476A0|1992-08-28|
    BE904587A|1986-10-13|
    IE59039B1|1993-12-15|
    AU3628889A|1989-10-05|
    AU617182B2|1991-11-21|
    AU3628489A|1989-10-05|
    GB2176181A|1986-12-17|
    PT82383B|1988-10-14|
    EG18077A|1991-08-30|
    US4644072A|1987-02-17|
    HUT44773A|1988-04-28|
    IT1208593B|1989-07-10|
    CN1021822C|1993-08-18|
    ATA96986A|1994-05-15|
    DK167986D0|1986-04-11|
    SG44791G|1991-07-26|
    AU3628589A|1989-10-05|
    FI861508A0|1986-04-09|
    AU617183B2|1991-11-21|
    YU46212B|1993-05-28|
    IL78451D0|1986-08-31|
    GB8608808D0|1986-05-14|
    SE9202476D0|1992-08-28|
    GB2176181B|1989-06-28|
    CA1275651C|1990-10-30|
    CN1059520A|1992-03-18|
    ZA862747B|1986-11-26|
    IT8620048D0|1986-04-11|
    YU44785B|1991-02-28|
    DK167986A|1986-10-13|
    YU59486A|1988-02-29|
    HU201541B|1990-11-28|
    HU198063B|1989-07-28|
    JPS61238758A|1986-10-24|
    LU86392A1|1986-11-05|
    ES8802044A1|1988-03-16|
    AU607337B2|1991-02-28|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    NL6613143A|1965-09-21|1967-03-22|
    US3716574A|1967-12-01|1973-02-13|Rayonier Inc|Pure crystalline plicatic acid tetrahydrate and the methyl ester thereof|
    US4122092A|1977-08-25|1978-10-24|University Of Rochester|Total synthesis of -picropodophyllone and -4'-demethylpicropodophyllone|
    US4294763A|1980-03-05|1981-10-13|University Of Rochester|Intermediates for the production of picropodophyllin and related compounds and processes for the preparation and use thereof|
    US4391982A|1980-03-05|1983-07-05|The University Of Rochester|Intermediates for the production of picropodophyllin and related compounds and processes for the preparation and use thereof|
    WO1986004062A1|1984-12-28|1986-07-17|Conpharm Ab|Pharmaceutically active compound and a method for its preparation|
    ES8705837A1|1985-01-10|1987-05-16|Tanabe Seiyaku Co|Naphthalene derivatives, process for the preparation thereof and pharmaceutical composition containing same.|
    US4644072A|1985-04-12|1987-02-17|Bristol-Myers Company|Intermediates for the production of epipodophyllotoxin and related compounds and processes for the preparation and use thereof|
    US4734512A|1985-12-05|1988-03-29|Bristol-Myers Company|Intermediates for the production of podophyllotoxin and related compounds and processes for the preparation and use thereof|US4644072A|1985-04-12|1987-02-17|Bristol-Myers Company|Intermediates for the production of epipodophyllotoxin and related compounds and processes for the preparation and use thereof|
    US5011948A|1985-04-12|1991-04-30|Bristol-Myers Company|Intermediates for the production of epipodophyllotoxin and related compounds and processes for the preparation and use thereof|
    US4734512A|1985-12-05|1988-03-29|Bristol-Myers Company|Intermediates for the production of podophyllotoxin and related compounds and processes for the preparation and use thereof|
    US5106996A|1985-12-05|1992-04-21|Bristol-Myers Company|Process for the preparation of podophyllotoxin|
    US5013851A|1985-12-05|1991-05-07|Bristol-Myers Company|Intermediates for the production of podophyllotoxin and related compounds|
    US5840900A|1993-10-20|1998-11-24|Enzon, Inc.|High molecular weight polymer-based prodrugs|
    US5880131A|1993-10-20|1999-03-09|Enzon, Inc.|High molecular weight polymer-based prodrugs|
    GB9422947D0|1994-11-14|1995-01-04|Univ Salamanca|Immunosuppressive cyclolignan derivatives|
    US5605976A|1995-05-15|1997-02-25|Enzon, Inc.|Method of preparing polyalkylene oxide carboxylic acids|
    EP0757055B1|1995-06-30|1999-10-27|Cerbios-Pharma S.A.|Glycosides, sugar-free degradation products and derivatives of the same|
    US6051721A|1997-10-02|2000-04-18|The Board Of Regents Of The University Of Nebraska|Ring E-modified analogues of-podophyllotoxin and etoposide and a method for their synthesis|
    EP2266607A3|1999-10-01|2011-04-20|Immunogen, Inc.|Immunoconjugates for treating cancer|
    MD3395821T2|2017-04-27|2019-10-31|Pharma Mar Sa|Antitumoral compounds|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US06/722,932|US4644072A|1985-04-12|1985-04-12|Intermediates for the production of epipodophyllotoxin and related compounds and processes for the preparation and use thereof|
    [返回顶部]